Trade

with

Pernix Therapeutics Holdings Inc
(NASDAQ: PTX)
AdChoices
9.01
-0.10
-1.10%
After Hours :
-
-
-

Open

9.14

Previous Close

9.11

Volume (Avg)

198.75k (483.29k)

Day's Range

8.99-9.22

52Wk Range

1.68-9.83

Market Cap.

346.96M

Dividend Rate ( Yield )

-

Beta

1.73

Shares Outstanding

38.04M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 84.87M

    • Net Income

    • -25.64M

    • Market Cap.

    • 346.96M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -35.37

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.73

    • Forward P/E

    • -454.55

    • Price/Sales

    • 4.33

    • Price/Book Value

    • 3.56

    • Price/Cash flow

    • -21.19

      • EBITDA

      • -45.98M

      • Return on Capital %

      • -10.75

      • Return on Equity %

      • -29.43

      • Return on Assets %

      • -10.75

      • Book Value/Share

      • 2.56

      • Shares Outstanding

      • 38.04M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.50 (8/21/2001)

      • Dividend Declaration Date

      • 8/10/2001

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 9.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 0.35

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -15.50

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 51.32

            • 64.72

            • Pre-Tax Margin

            • -67.48

            • 13.77

            • Net Profit Margin

            • -35.37

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.67

              • 0.33

              • Current Ratio

              • 1.82

              • 1.52

              • Quick Ratio

              • 1.38

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 2.60

              • 1.91

              • Book Value/Share

              • 2.56

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -12.33

                • 63.69

                • P/E Ratio 5-Year High

                • -17.76

                • 237.47

                • P/E Ratio 5-Year Low

                • -2.26

                • 19.71

                • Price/Sales Ratio

                • 4.36

                • 3.64

                • Price/Book Value

                • 3.59

                • 3.39

                • Price/Cash Flow Ratio

                • -21.19

                • 21.79

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -29.43

                    (11.60)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -10.75

                    (6.10)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -19.05

                    (8.20)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 2.43

                  • 1.80

                  • Asset Turnover

                  • 0.30

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -54.66M
                  Operating Margin
                  -64.40
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -21.19
                  Ownership

                  Institutional Ownership

                  63.27%

                  Top 10 Institutions

                  39.78%

                  Mutual Fund Ownership

                  16.95%

                  Float

                  53.13%

                  5% / Insider Ownership

                  23.74%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • F&C Global Smaller Companies

                  •  

                    638,257

                  • 0.00

                  • 1.68

                  • Jupiter US Smaller Companies

                  •  

                    576,821

                  • 0.00

                  • 1.54

                  • iShares Russell 2000 (AU)

                  •  

                    518,706

                  • -0.89

                  • 1.63

                  • Vanguard Total Stock Mkt Idx

                  •  

                    392,428

                  • 0.00

                  • 1.03

                  • Foreign & Colonial Investment Trust

                  •  

                    299,823

                  • 0.00

                  • 0.79

                  • F&C US Smaller Comp Fd

                  •  

                    287,148

                  • 0.00

                  • 0.75

                  • iShares Russell 2000 Growth

                  •  

                    240,220

                  • -0.45

                  • 0.75

                  • CREF Stock

                  •  

                    167,872

                  • 2.21

                  • 0.44

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Broadfin Capital, LLC

                  •  

                    3,500,000

                  • 0.00%

                  • 9.20

                  • Consonance Capital Management LP

                  •  

                    3,024,851

                  • +148.51%

                  • 7.95

                  • Orbimed Advisors, LLC

                  •  

                    1,130,600

                  • -48.57%

                  • 2.97

                  • Janus Capital Management LLC

                  •  

                    864,469

                  • +89.24%

                  • 2.27

                  • BlackRock Fund Advisors

                  •  

                    819,013

                  • +69.67%

                  • 2.15

                  • F&C Asset Management PLC

                  •  

                    638,257

                  • 0.00%

                  • 1.68

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Core

                  Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products...more primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX®, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR® (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak® through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumbe...morerland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO®; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.lessless

                  Key People

                  Mr. Douglas Drysdale

                  CEO/Chairman of the Board/Director

                  Mr. Sanjay Patel

                  CFO

                  John A. Sedor

                  Director

                  Steven A. Elms

                  Director

                  Mr. Tasos G. Konidaris

                  Independent Director

                  • Pernix Therapeutics Holdings Inc

                  • 10863 Rockley Road

                  • Houston, TX 77099

                  • USA.Map

                  • Phone: +1 832 934-1825

                  • Fax: +1 800 793-2145

                  • pernixtx.com

                  Incorporated

                  1996

                  Employees

                  191

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: